Amiloride ( DrugBank: Amiloride )
4 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 5 |
| 67 | 多発性嚢胞腎 | 1 |
| 225 | 先天性腎性尿崩症 | 3 |
| 299 | 嚢胞性線維症 | 3 |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01910259 (ClinicalTrials.gov) | December 18, 2014 | 19/7/2013 | MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial | A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis. | Secondary Progressive Multiple Sclerosis | Drug: Amiloride;Drug: Riluzole;Drug: Fluoxetine;Drug: Placebo | University College, London | Medical Research Council;National Institute for Health Research, United Kingdom;MS Society;University of Edinburgh;Queen Mary University of London;Keele University;University of Sheffield;University of Leeds;University of Warwick | Completed | 25 Years | 65 Years | All | 445 | Phase 2 | United Kingdom |
| 2 | EUCTR2012-005394-31-GB (EUCTR) | 01/04/2014 | 05/09/2014 | MS-SMART: A Trial of Efficacy (usefulness) of 3 Neuroprotective Drugs in SPMS | MS-SMART: A Multi-Arm Phase IIb Randomised, Double Blind Placebo-Controlled Clinical Trial Comparing The Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis - MS-SMART: Multiple Sclerosis Secondary Progressive Multi-Arm Randomisation Trial | Mutliple Sclerosis (Secondary Progressive);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Rilutek Product Name: Rilutek INN or Proposed INN: Riluzole Trade Name: Amiloride Product Name: Amiloride INN or Proposed INN: Amiloride Trade Name: Fluoxetine Product Name: Fluoxetine INN or Proposed INN: Fluoxetine hydrochloride | UCL | NULL | Not Recruiting | Female: yes Male: yes | 440 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United Kingdom | ||
| 3 | EUCTR2012-005113-39-AT (EUCTR) | 08/04/2013 | 18/02/2013 | Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve. | A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis - Amiloride Hydrochlorothiazide in acute autoimmune optic neuritis | Optic neuritis is among the most common first symptoms of multiple sclerosis leading to significant atrophy of the optic nerve within a short period of time, thus reflecting neurodegneration.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Amilostad HCT Product Name: Amilostad HCT tablets INN or Proposed INN: AMILORIDE HYDROCHLORIDE, 2 H2O Other descriptive name: Amiloride Hydrochloride INN or Proposed INN: hydrochlorothiazide Other descriptive name: HYDROCHLOROTHIAZIDE | Universitätsklinik für Neurologie, Medizinische Universität Wien | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | Austria | |||
| 4 | NCT01802489 (ClinicalTrials.gov) | February 2013 | 27/2/2013 | Amiloride Clinical Trial In Optic Neuritis | A Double Blind Randomised Control Trial on Neuroprotection of Amiloride in Optic Neuritis | Optic Neuritis;Multiple Sclerosis | Drug: Amiloride;Drug: Placebo | University of Oxford | Multiple Sclerosis Society of Great Britain and Northern Ireland | Completed | 18 Years | 55 Years | All | 46 | Phase 2 | United Kingdom |
| 5 | EUCTR2007-004051-11-GB (EUCTR) | 18/12/2008 | 15/07/2008 | Amiloride Treatment in Multiple Sclerosis - Amiloride in MS | Amiloride Treatment in Multiple Sclerosis - Amiloride in MS | Multiple Sclerosis | Trade Name: Amiloride Product Name: Amiloride Hydrochloride | Oxford Racliffe NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | 23 | United Kingdom |
67. 多発性嚢胞腎
臨床試験数 : 216 / 薬物数 : 219 - (DrugBank : 50) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-000433-40-NL (EUCTR) | 30/12/2021 | 03/08/2021 | Treatment of stiffness in blood vessels in patients with familial cystic kidney disease | Treatment of vascular stiffness in patients with autosomal dominant polycystic kidney disease - TRAMPOLINE | Autosomal dominant polycystic kidney disease;Therapeutic area: Not possible to specify | Trade Name: Amiloride Product Name: Amiloride INN or Proposed INN: AMILORIDE Trade Name: Sodium Chloride INN or Proposed INN: Sodium chloride Other descriptive name: Sodium Chloride | Erasmus University Medical Centre Rotterdam | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 54 | Phase 4 | Netherlands |
225. 先天性腎性尿崩症
臨床試験数 : 15 / 薬物数 : 48 - (DrugBank : 18) / 標的遺伝子数 : 31 - 標的パスウェイ数 : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05044611 (ClinicalTrials.gov) | April 1, 2022 | 27/8/2021 | AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium | AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium: a Randomized Controlled Trial | Bipolar Disorder | Drug: Anhydrous Amiloride Hydrochloride;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 18 Years | N/A | All | 148 | Phase 4 | NULL |
| 2 | NCT00478335 (ClinicalTrials.gov) | May 2007 | 23/5/2007 | Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus | Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus | Nephrogenic Diabetes Insipidus | Drug: sildenafil;Drug: calcitonin;Drug: hydrochlorothiazide/amiloride;Drug: indomethacin;Drug: Placebo for sildenafil;Drug: placebo for calcitonin | University of Colorado, Denver | University of Aarhus | Completed | 5 Years | 25 Years | Male | 4 | N/A | United States;Denmark |
| 3 | EUCTR2006-001202-84-NL (EUCTR) | 01/02/2007 | 31/01/2007 | Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDI | Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDI | Lithium-induced Nephrogenic Diabetes Insipidus MedDRA version: 9.1;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic | Trade Name: Midamor Product Name: Amiloride Trade Name: Hydrochloorthiazide Product Name: hydrochloorthiazide | Radboud University Nijmegen Medical Centre | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 4 | Netherlands |
299. 嚢胞性線維症
臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00547053 (ClinicalTrials.gov) | December 2006 | 17/10/2007 | Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis | A Six Month Open Label Study of Amiloride Solution for Inhalation and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis | Cystic Fibrosis | Drug: Amiloride Solution for Inhalation | Children's Hospital Boston | Cystic Fibrosis Foundation Therapeutics | Completed | 6 Years | N/A | Both | 25 | Phase 1 | United States |
| 2 | NCT00274391 (ClinicalTrials.gov) | July 2001 | 9/1/2006 | Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis | Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis | Cystic Fibrosis | Drug: 7% NaCl;Drug: Amiloride HCl | University of North Carolina | Cystic Fibrosis Foundation Therapeutics | Completed | 14 Years | N/A | Both | 24 | Phase 2 | United States |
| 3 | NCT00004705 (ClinicalTrials.gov) | September 1996 | 24/2/2000 | Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis | Cystic Fibrosis | Drug: amiloride;Drug: uridine | FDA Office of Orphan Products Development | University of North Carolina | Completed | 4 Years | N/A | Both | N/A | NULL |